A Phase I Clinical Trial of Ad5/3-Δ24, a Novel Serotype-Chimeric, Infectivity-Enhanced, Conditionally-Replicative Adenovirus (CRAd), in Patients with Recurrent Ovarian Cancer

OBJECTIVE: The conditionally replicative adenovirus Ad5/3-Δ24 has a type-3 knob incorporated into the type-5 fiber that facilitates enhanced ovarian cancer infectivity. Preclinical studies have shown that Ad5/3-Δ24 achieves significant oncolysis and antitumor activity in ovarian cancer models. The p...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Kim, Kenneth H., Dmitriev, Igor P., Saddekni, Souheil, Kashentseva, Elena A., Harris, Raymond D., Aurigemma, Rosemarie, Bae, Sejong, Singh, Karan P., Siegal, Gene P., Curiel, David T., Alvarez, Ronald D.
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3748258/
https://ncbi.nlm.nih.gov/pubmed/23756180
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2013.06.003
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados